摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

盐酸前鸦片碱 | 6164-47-2

中文名称
盐酸前鸦片碱
中文别名
盐酸普罗托平/蓝堇碱
英文名称
protopine hydrochloride
英文别名
Hydron;15-methyl-7,9,19,21-tetraoxa-15-azapentacyclo[15.7.0.04,12.06,10.018,22]tetracosa-1(17),4,6(10),11,18(22),23-hexaen-3-one;chloride;hydron;15-methyl-7,9,19,21-tetraoxa-15-azapentacyclo[15.7.0.04,12.06,10.018,22]tetracosa-1(17),4,6(10),11,18(22),23-hexaen-3-one;chloride
盐酸前鸦片碱化学式
CAS
6164-47-2
化学式
C20H19NO5*ClH
mdl
——
分子量
389.835
InChiKey
NWNVDSJZGYDVQW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 溶解度:
    溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。
  • 颜色/状态:
    PRISMS FROM ALC
  • 稳定性/保质期:
    在常温常压下,该物质保持稳定。

计算性质

  • 辛醇/水分配系数(LogP):
    2.98
  • 重原子数:
    27
  • 可旋转键数:
    0
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    57.2
  • 氢给体数:
    1
  • 氢受体数:
    6

ADMET

毒理性
  • 副作用
神经毒素 - 其他中枢神经系统神经毒素
Neurotoxin - Other CNS neurotoxin
来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases
毒理性
  • 非人类毒性摘录
当以0.5-10毫克/千克静脉注射到兔或大鼠体内时,盐酸原托品会降低房室结和心脏内的传导性,导致心脏收缩频率降低。在1-100微克/毫升的浓度下,它会减少由巴氯芬(0.8毫克/毫升)诱导的大鼠离体肠段收缩。
WHEN INJECTED IV @ 0.5-10 MG/KG INTO RABBITS OR RATS, PROTOPINE-HCL DECR THE ATRIOVENTRICULAR AND INTRACARDIAC CONDUCTIVITY LEADING TO A DECR IN THE FREQUENCY OF CARDIAC CONTRACTIONS. AT 1-100 MUG/ML, IT DECR THE CONTRACTIONS OF AN ISOLATED RAT INTESTINAL SEGMENT INDUCED BY BACL2 (0.8 MG/ML).
来源:Hazardous Substances Data Bank (HSDB)

安全信息

  • 危险等级:
    6.1(b)
  • 危险品标志:
    T
  • 安全说明:
    S36/37/39,S45
  • 危险类别码:
    R25
  • WGK Germany:
    3
  • 包装等级:
    III
  • 危险类别:
    6.1(b)

制备方法与用途

制备方法

生化研究、医药

用途简介 用途

生化研究、医药

反应信息

  • 作为反应物:
    描述:
    盐酸前鸦片碱 反应 960.0h, 以24 mg的产率得到13,14-二氢血根碱
    参考文献:
    名称:
    延胡索愈伤组织培养中生物碱的形成
    摘要:
    摘要 研究了紫堇属愈伤组织的异喹啉生物碱含量。该培养物对转化外源生物碱具有良好的生物合成能力。
    DOI:
    10.1016/0031-9422(82)83151-8
点击查看最新优质反应信息

文献信息

  • METHODS FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS
    申请人:GRIFFITH UNIVERSITY
    公开号:US20210069180A1
    公开(公告)日:2021-03-11
    In one aspect the invention relates to a method of treatment selected from the group consisting of: (a) treating a symptom such as pain in a subject identified or diagnosed as having Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS); (b) treating a symptom such as pain in a subject having dysfunctional TRPM3 ion channel activity; (c) restoring NK cell function in a subject having dysfunctional TRPM3 ion channel activity; and (d) restoring calcium homeostasis in a subject having dysfunctional TRPM3 ion channel activity. The method comprises the step of administering to the subject a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of: (i) an opioid receptor antagonist; (ii) an opioid antagonist; and (iii) a therapeutic compound that restores TRPM3 ion channel activity. In some embodiments the therapeutic compound is naltrexone hydrochloride.
    在一个方面,该发明涉及一种治疗方法,所述方法选自以下组合:(a)治疗被识别或诊断为患有肌无力性脑脊髓炎/慢性疲劳综合征(ME/CFS)的受试者的症状,例如疼痛;(b)治疗具有TRPM3离子通道活性异常的受试者的症状,例如疼痛;(c)恢复具有TRPM3离子通道活性异常的受试者的NK细胞功能;以及(d)恢复具有TRPM3离子通道活性异常的受试者的钙稳态。该方法包括向受试者施用来自以下组合的至少一种治疗化合物的治疗有效量的步骤:(i)阿片受体拮抗剂;(ii)阿片拮抗剂;以及(iii)恢复TRPM3离子通道活性的治疗化合物。在某些实施例中,治疗化合物是盐酸纳曲酮。
  • METHODS AND APPARATUS FOR NEAR FIELD IRRADIATION
    申请人:The President and Fellows of Harvard College
    公开号:EP1996320A2
    公开(公告)日:2008-12-03
  • DIAGNOSTIC METHODS
    申请人:Griffith University
    公开号:EP3289106A1
    公开(公告)日:2018-03-07
  • Methods and Apparatus for Near Field Irradiation
    申请人:Issadore David
    公开号:US20090220968A1
    公开(公告)日:2009-09-03
    Irradiation methods and apparatus configured to deliver power, via electromagnetic fields at a variety of frequencies and power levels, in a localized fashion to a target area. In one example, an electromagnetic field generator is disposed on a substrate and configured to deliver power via electromagnetic energy to a thin region proximate to (above) a surface of the substrate, wherein electromagnetic field intensity decreases significantly beyond the thin region. Such methods and apparatus are particularly useful in a wide variety of processes involving chemical and/or physical interactions in connection with a sample of interest located in the thin region. In different aspects, irradiator apparatus may be configured as disposable devices, and/or used in combination with one or more microfluidic or sensing components, for a variety of medical/laboratory/diagnostic methods and instrumentation implementations.
  • [EN] METHODS AND APPARATUS FOR NEAR FIELD IRRADIATION<br/>[FR] PROCEDES ET APPAREIL POUR IRRADIATION EN CHAMP PROCHE
    申请人:HARVARD COLLEGE
    公开号:WO2007106402A2
    公开(公告)日:2007-09-20
    [EN] Irradiation methods and apparatus configured to deliver power, via electromagnetic fields at a variety of frequencies and power levels, in a localized fashion to a target area. In one example, an electromagnetic field generator is disposed on a substrate and configured to deliver power via electromagnetic energy to a thin region proximate to (above) a surface of the substrate, wherein electromagnetic field intensity decreases significantly beyond the thin region. Such methods and apparatus are particularly useful in a wide variety of processes involving chemical and/or physical interactions in connection with a sample of interest located in the thin region. In different aspects, irradiator apparatus may be configured as disposable devices, and/or used in combination with one or more microfluidic or sensing components, for a variety of medical / laboratory / diagnostic methods and instrumentation implementations.
    [FR] La présente invention concerne des procédés et un appareil d'irradiation configurés pour fournir de l'énergie, par des champs électromagnétiques à une diversité de fréquences et de niveaux énergétiques, d'une manière localisée sur une zone cible. Dans un exemple, un générateur de champ électromagnétique est disposé sur un substrat et configuré pour fournir de l'énergie par une énergie électromagnétique à une région mince à proximité (au-dessus) d'une surface du substrat, l'intensité du champ électromagnétique décroissant de manière significative au-delà de la région mince. De tels procédés et appareil sont particulièrement utiles dans une large diversité de procédés mettant en jeu des interactions chimiques et/ou physiques en rapport avec un échantillon d'intérêt situé dans la région mince. Dans différents aspects, l'appareil irradiant peut être configuré sous forme de dispositifs jetables et/ou utilisé en combinaison avec un ou plusieurs composants microfluidiques ou de détection, pour une diversité de procédés médicaux/de laboratoire/diagnostiques et des mises en application d'instrumentation.
查看更多

同类化合物

隐掌叶防己碱 隐品碱 紫菫醚 紫堇文碱 盐酸前鸦片碱 原阿片碱 别隐品碱 伪原阿片碱 5,7,8,15-四氢-4-羟基-3-甲氧基-6-甲基(1,3)苯并二氧戊环并(5,6-e)(2)苯并氮杂环癸烷-14(6H)-酮 1-甲氧基别隐品碱 3,4-dimethoxy-6-methyl-5,7,8,15-tetrahydro-6H-benzo[c][1,3]dioxolo[4',5':4,5]benz[1,2-g]azecin-14-one; hydrochloride tert-butyl (2S,3S)-2-(8-(benzyloxy)-1,5-dihydroxy-3-methyl-7,12-dioxobenzo[b]phenanthridin-6(5H,7H,12H)-yl)-3-methylpentanoate corycavidine corycavamine Corycavidine hydrochloride 5,6,7,8,13,14-hexahydro-7-methyl-2,3-dimethoxydibenzazecin-14-one 12-bromo-7-methyl-2,3,9,10-tetramethoxy-5,6,7,8,13,14-hexahydrodibenz[c,g]azecine-8,14-dione 12-bromo-5,6,7,8,13,14-hexahydro-7-methyl-2,3,9,10-bis(methylenedioxy)dibenz[c,g]azecine-8,14-dione Protopine-M (demethylene-methyl-) isomer-2, AC 7,8-dimethoxy-11-methyl-17,19-dioxa-11-azatetracyclo[12.7.0.04,9.016,20]henicosa-1(21),4(9),5,7,14,16(20)-hexaen-2-one;3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Protopine-M (demethylene-methyl-) isomer-1, AC 6-Hydroxy-allocryptopine (3R)-7,8-dimethoxy-3,11-dimethyl-17,19-dioxa-11-azatetracyclo[12.7.0.04,9.016,20]henicosa-1(21),4(9),5,7,14,16(20)-hexaen-2-one;(3S)-7,8-dimethoxy-3,11-dimethyl-17,19-dioxa-11-azatetracyclo[12.7.0.04,9.016,20]henicosa-1(21),4(9),5,7,14,16(20)-hexaen-2-one (2R)-2,15-dimethyl-7,9,19,21-tetraoxa-15-azapentacyclo[15.7.0.04,12.06,10.018,22]tetracosa-1(17),4,6(10),11,18(22),23-hexaen-3-one;(2S)-2,15-dimethyl-7,9,19,21-tetraoxa-15-azapentacyclo[15.7.0.04,12.06,10.018,22]tetracosa-1(17),4,6(10),11,18(22),23-hexaen-3-one 5,6,7,8,13,14-hexahydro-7-methyldibenzazecin-14-one 4-[[8-(4,5-dihydroxy-6-methyloxan-2-yl)oxy-1-hydroxy-5-methoxy-3-methyl-7,12-dioxo-5H-benzo[b]phenanthridin-6-yl]methyl]benzoic acid (±)-corycavidine (+/-)-corycavine 3-[[5-(carboxymethyl)-8-(4,5-dihydroxy-6-methyloxan-2-yl)oxy-1-hydroxy-3-methyl-7,12-dioxo-5H-benzo[b]phenanthridin-6-yl]methyl]benzoic acid 3-[[8-(4,5-dihydroxy-6-methyloxan-2-yl)oxy-1-hydroxy-5-methoxy-3-methyl-7,12-dioxo-5H-benzo[b]phenanthridin-6-yl]methyl]benzoic acid 13-oxocryptopine Coulteropin 3,10-dimethoxy-14H-benzo[e][2]benzazecin-13-one 6-Hydroxyprotopine 13-Oxo-muramin 4-[[8-(4,5-dihydroxy-6-methyloxan-2-yl)oxy-1,5-dihydroxy-3-methyl-7,12-dioxo-5H-benzo[b]phenanthridin-6-yl]methyl]benzoic acid 3,10-dihydroxy-14H-benzo[e][2]benzazecin-13-one 7,8,21-Trimethoxy-11-methyl-17,19-dioxa-11-azatetracyclo[12.7.0.04,9.016,20]henicosa-1(21),4(9),5,7,14,16(20)-hexaene-2,3-dione 4-[[5-(2-carboxy-2-oxoethyl)-8-(4,5-dihydroxy-6-methyloxan-2-yl)oxy-1-hydroxy-3-methyl-7,12-dioxo-5H-benzo[b]phenanthridin-6-yl]methyl]benzoic acid 4-Hydroxy-3,10,11-trimethoxy-6-methyl-5,7,8,14-tetrahydrobenzo[e][2]benzazecin-13-one 6,7-Dimethoxy-11-methyl-17,19-dioxa-11-azatetracyclo[12.7.0.04,9.016,20]henicosa-1(21),4,6,8,14,16(20)-hexaene-2,3-dione 7,8-Dihydroxy-11-methyl-17,19-dioxa-11-azatetracyclo[12.7.0.04,9.016,20]henicosa-1(21),4(9),5,7,14,16(20)-hexaen-2-one argemexicaine A 13-oxoprotopine 8-(4,5-dihydroxy-6-methyloxan-2-yl)oxy-1-hydroxy-5-methoxy-3-methyl-6-(2-oxopiperidin-3-yl)-5H-benzo[b]phenanthridine-7,12-dione 9-demethylallocryptopine 1,2-Dimethoxy-7-methyl-5H,6H,8H,11H,14H-benzo[1'',2''-4',5']azecino[9',8'-2,1]benzo[4,5-d]1,3-dioxolan-15-one 5,6-dihydro-3,5-di-O-methylconstrictosine leptocarpine 12-Methyl-6,8,18,20-tetraoxa-12-azahexacyclo[11.11.0.02,10.05,9.015,23.017,21]tetracosa-2(10),3,5(9),15,17(21),22-hexaen-24-one